https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31235 HI monocytes/macrophages and neutrophils. Body weight and clinical scores were recorded throughout the experiment. Results: We demonstrate that KB treatment attenuated cigarette smoke-induced lung inflammation as shown by reductions in levels of BAL IFNγ, CXCL9, CXCL10, CCL5, IL-6, G-CSF, and IL-17. KB additionally attenuated the quantity of BAL lymphocytes and macrophages. In parallel to the attenuation of lung inflammation, KB induced a systemic immune activation with increases in Ly6C^HI monocytes/macrophages and neutrophils. Conclusions: This is the first demonstration that subcutaneous administration of a microbial-based immunotherapy can attenuate cigarette smoke-induced lung inflammation, and modulate BAL lymphocyte and macrophage levels, while inducing a systemic immune activation and mobilization. These data provide a foundation for future studies exploring how KB may be used to either reverse or prevent progression of established emphysema and small airways disease associated with chronic cigarette smoke exposure. The data suggest the intriguing possibility that KB, which stimulates rather than suppresses systemic immune responses, might be a novel means by which the course of COPD pathogenesis may be altered.]]> Wed 10 Nov 2021 15:05:01 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48564 Tue 21 Mar 2023 15:51:48 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19679 Sat 24 Mar 2018 07:53:38 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22734 Sat 24 Mar 2018 07:12:22 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46206 Mon 14 Nov 2022 11:29:50 AEDT ]]>